Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human TRAIL R4 (Internal Domain) - 20 µg | Login | Anti-Human TRAIL R4 (Internal Domain) - 20 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Ras Homolog Enriched in Brain (NT) (Rheb) - 0.1 mg | Login | Anti-Human Ras Homolog Enriched in Brain (NT) (Rheb) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Ras Homolog Enriched in Brain (Intermediate Domain) ( - 0.1 mg | Login | Anti-Human Ras Homolog Enriched in Brain (Intermediate Domain) ( - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-PCNA – Purified (PhenoCyler-Fusion (CODEX)® Ready) - 50 µg | Login | Anti-PCNA – Purified (PhenoCyler-Fusion (CODEX)® Ready) - 50 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human MyD88 (CT) - 20 µg | Login | Anti-Human MyD88 (CT) - 20 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human MyD88 (Intermediate Domain) - 20 µg | Login | Anti-Human MyD88 (Intermediate Domain) - 20 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) - 1.0 mg | Login | Anti-Human EGFR (Necitumumab) - 1.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) - 100 mg | Login | Anti-Human EGFR (Necitumumab) - 100 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) - 25 mg | Login | Anti-Human EGFR (Necitumumab) - 25 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) - 5.0 mg | Login | Anti-Human EGFR (Necitumumab) - 5.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) - 50 mg | Login | Anti-Human EGFR (Necitumumab) - 50 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Necitumumab) – Fc Muted™ - 500 µg | Login | Anti-Human EGFR (Necitumumab) – Fc Muted™ - 500 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) - 100 mg | Login | Anti-Human EGFR (Panitumumab) - 100 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) - 1.0 mg | Login | Anti-Human EGFR (Panitumumab) - 1.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) - 25 mg | Login | Anti-Human EGFR (Panitumumab) - 25 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) - 5.0 mg | Login | Anti-Human EGFR (Panitumumab) - 5.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) – Fc Muted™ - 500 µg | Login | Anti-Human EGFR (Panitumumab) – Fc Muted™ - 500 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) - 5.0 mg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) - 5.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) - 1.0 mg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) - 1.0 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) – Fc Muted™ - 500 µg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) – Fc Muted™ - 500 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Panitumumab) - 50 mg | Login | Anti-Human EGFR (Panitumumab) - 50 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) - 25 mg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) - 25 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) - 50 mg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) - 50 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human CD276 (B7-H3) (Mirzotamab) - 100 mg | Login | Anti-Human CD276 (B7-H3) (Mirzotamab) - 100 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human EGFR (Cetuximab) [Clone C225] - 1.0 mg | Login | Anti-Human EGFR (Cetuximab) [Clone C225] - 1.0 mg | ||||||||||||||||
|
||||||||||||||||||


